Korro Bio (KRRO) Projected to Post Earnings on Tuesday

Korro Bio (NASDAQ:KRRO) is projected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Korro Bio to post earnings of ($2.41) per share for the quarter.

Korro Bio Price Performance

KRRO stock opened at $25.06 on Tuesday. Korro Bio has a twelve month low of $18.50 and a twelve month high of $98.00. The firm has a 50 day simple moving average of $30.99 and a 200-day simple moving average of $41.99.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Korro Bio in a report on Friday, November 22nd. Oppenheimer assumed coverage on shares of Korro Bio in a report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Korro Bio currently has a consensus rating of “Buy” and a consensus price target of $144.00.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).